1. Home
  2. FRAF vs SGMT Comparison

FRAF vs SGMT Comparison

Compare FRAF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Financial Services Corporation

FRAF

Franklin Financial Services Corporation

HOLD

Current Price

$49.07

Market Cap

229.0M

Sector

Finance

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$5.21

Market Cap

164.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRAF
SGMT
Founded
1906
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
229.0M
164.6M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
FRAF
SGMT
Price
$49.07
$5.21
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$27.00
AVG Volume (30 Days)
16.8K
352.1K
Earning Date
01-01-0001
06-10-2026
Dividend Yield
2.67%
N/A
EPS Growth
N/A
N/A
EPS
3.39
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$4,523.58
P/E Ratio
$14.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.53
$1.73
52 Week High
$57.51
$11.41

Technical Indicators

Market Signals
Indicator
FRAF
SGMT
Relative Strength Index (RSI) 42.68 41.75
Support Level $47.25 $4.97
Resistance Level $53.59 $6.49
Average True Range (ATR) 1.67 0.34
MACD -0.30 -0.01
Stochastic Oscillator 29.69 7.02

Price Performance

Historical Comparison
FRAF
SGMT

About FRAF Franklin Financial Services Corporation

Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: